Navigation Links
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Date:8/29/2007

a scientific publication.

"The initiation of an advanced Phase II clinical trial with GTI-2040 is a very significant step forward for Lorus, and for the development of its clinical stage pipeline. This underscores the dedication of Lorus' clinical and regulatory teams to the development of novel anticancer agents," commented Dr. Aiping Young, President & CEO of Lorus. "The clinical data for GTI-2040 in AML are consistent with an antisense mode of action, and the frequency of responses and statistical correlation of this with target activity are very encouraging. We believe that this drug will provide an important new treatment opportunity for AML patients."

This new advanced Phase II clinical trial is sponsored by Lorus and is being led by Dr. Rebecca Klisovic as Principal Investigator and Dr. Guido Marcucci as co-investigator, at The Comprehensive Cancer Center of Ohio State University. Dr. Marcucci was also the Principal Investigator on the previous clinical trial of GTI-2040 in AML, which was carried out with the sponsorship of the Cancer Therapy Evaluation Program of the US National Cancer Institute. Dr. Marcucci and his team at OSU have extensive experience with antisense and other targeted therapies in leukemic indications and in genetic studies of leukemia.

Ara-C, including HiDAC, is a key component of nearly all AML regimens, for induction, consolidation or salvage treatment. However even with intensification of the Ara-C, response to treatment in refractory and relapsed disease is limited by development of increasing resistance to Ara-C with repeated exposures. Combining GTI-2040 with Ara-C is a rational approach that in addition to potential cooperative activities may overcome resistance to Ara-C.

About GTI-2040

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, GTI-2040 has demonstrated
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. BioRobot MDx standardize your automated protocols in clinical laboratories
11. What patients want: A story of choice, clinical trials & evidence-based medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... June 28, 2011 While the health benefits of oregano ... organic Oregano Oil blend from Global Healing Center is one ... market, which is exactly why it,s gaining popularity as a ... contains a minimum of 80% Carvacrol, a compound that is ...
... LA JOLLA, Calif., June 27, 2011 Celladon Corp., ... of innovative treatments for cardiovascular diseases, announces that the ... of MYDICAR® for the treatment of advanced heart failure ... Heart Association journal. "I am very ...
... Pa., June 27, 2011 Morphotek®, Inc., a subsidiary of ... campaign to collect 8,792 pounds of food from its employees, ... year. With approximately 200 employees at Morphotek, this number equates ... food will be donated to local needy families through collaboration ...
Cached Biology Technology:Organic Oregano Oil Gaining Popularity in Natural Health Field, According to Global Healing Center 2Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 2Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 3Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation 4Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 2Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 3
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... of Ascension Island, one of the world,s largest green ... Writing in the journal Biodiversity and Conservation , ... Government Conservation Department report that the number of green ... increased by more than 500 per cent since records ... are now estimated to be laid on the Island,s ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... AKRON, Ohio, June 16, 2011 Leaders within the ... to apply "Value-driven Engineering" (VdE) to enhance the development ... efficiency and reduced complexity.  VdE will become a key ... economy," maintain global competitiveness, and assure access to device ...
... Robert Blelloch, MD, PhD, has received the 2011 Outstanding Young ... for his pioneering research on the role of molecular tools ... Blelloch will present his research today, June 15, 2011, at ... p.m. EDT). He will participate in a press briefing at ...
... new Baylor University study has found that sunlight decreases the ... the southern United States every year. While golden algae ... Texas rivers and lakes, including Lake Whitney and Lake Waco ... believe that several environmental factors influence toxin production, but new ...
Cached Biology News:U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 2U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 3U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 4UCSF stem cell, cancer scientist honored for pioneering studies 2UCSF stem cell, cancer scientist honored for pioneering studies 3
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: